The estimated Net Worth of Sandra Phd Panem is at least $20.2 Milión dollars as of 12 December 2014. Sandra Panem owns over 10,000 units of Acorda Therapeutics Inc stock worth over $8,522 and over the last 19 years he sold ACOR stock worth over $20,008,560. In addition, he makes $135,898 as Independent Director at Acorda Therapeutics Inc.
Sign up
Sandra Panem ACOR stock SEC Form 4 insiders trading
Sandra has made over 17 trades of the Acorda Therapeutics Inc stock since 2006, according to the Form 4 filled with the SEC. Most recently he exercised 10,000 units of ACOR stock worth $316,100 on 12 December 2014.
The largest trade he's ever made was selling 200,000 units of Acorda Therapeutics Inc stock on 5 August 2010 worth over $7,182,000. On average, Sandra trades about 22,551 units every 87 days since 2006. As of 12 December 2014 he still owns at least 12,912 units of Acorda Therapeutics Inc stock.
You can see the complete history of Sandra Panem stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sandra Panem biography
Dr. Sandra Panem Ph.D. serves as Independent Director of the Company since 1998. She is currently a partner at Cross Atlantic Partners, which she joined in 2000. She is also currently President of NeuroNetworks Fund, a not-for-profit venture capital fund focusing on neurodisorders which she co-founded in December 2014. From 1994 to 1999, Dr. Panem was President of Vector Fund Management, the then asset management affiliate of Vector Securities International. Prior thereto, Dr. Panem served as Vice President and Portfolio Manager for the Oppenheimer Global BioTech Fund, a mutual fund that invested in public and private biotechnology companies. Previously, she was Vice President at Salomon Brothers Venture Capital, a fund focused on early and later-stage life sciences and technology investments. Dr. Panem was also a Science and Public Policy Fellow in economic studies at the Brookings Institution, and an Assistant Professor of Pathology at the University of Chicago. She received a B.S. in biochemistry and a Ph.D. in microbiology from the University of Chicago. Dr. Panem currently serves on the board of directors of BioLineRx Ltd. Dr. Panem’s experience investing in life sciences companies, and her long-standing relationship with the Company as a Board representative of one of its earliest investors, provides historical perspective on the Company and the life sciences industry. Based on her broad industry and corporate experience, Dr. Panem serves as Chair of our Nominations and Governance Committee.
What is the salary of Sandra Panem?
As the Independent Director of Acorda Therapeutics Inc, the total compensation of Sandra Panem at Acorda Therapeutics Inc is $135,898. There are 10 executives at Acorda Therapeutics Inc getting paid more, with Ron Cohen having the highest compensation of $2,039,560.
How old is Sandra Panem?
Sandra Panem is 73, he's been the Independent Director of Acorda Therapeutics Inc since 1998. There are 1 older and 16 younger executives at Acorda Therapeutics Inc. The oldest executive at Acorda Therapeutics Inc is Lorin Randall, 76, who is the Independent Director.
Insiders trading at Acorda Therapeutics Inc
Over the last 19 years, insiders at Acorda Therapeutics Inc have traded over $155,173,492 worth of Acorda Therapeutics Inc stock and bought 1,139,691 units worth $17,085,546 . The most active insiders traders include Capital Management Lp Scopi..., Ian F Smith a Ron Cohen. On average, Acorda Therapeutics Inc executives and independent directors trade stock every 19 days with the average trade being worth of $19,752. The most recent stock trade was executed by Ron Cohen on 16 March 2023, trading 20,156 units of ACOR stock currently worth $12,497.
What does Acorda Therapeutics Inc do?
acorda therapeutics is a publicly traded (nasdaq: acor) biotechnology company whose mission is to develop therapies that restore neurological function and improve the lives of people with neurological disorders. we started our company in 1995 as a network of scientists, physicians and business people with a common belief that sharing ideas and information could lead to innovative medical advances for people with neurological disorders. we have since evolved into a commercial-stage biotechnology company, successfully developing and commercializing important therapies that advance the care of people affected by neurological conditions. we achieve our goals by: • investing in research and development • collaborating closely with the patient, medical and scientific communities • retaining employees with compassion and commitment acorda has been voted one of the best companies to work for in new york for the past five years in a row, as a result of our dynamic environment, strong corporate
What does Acorda Therapeutics Inc's logo look like?
Complete history of Sandra Panem stock trades at Acorda Therapeutics Inc
Acorda Therapeutics Inc executives and stock owners
Acorda Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Ron Cohen,
President,Chief Executive Officer, Director -
Dr. Ron Cohen M.D.,
Founder, CEO, Pres & Director -
Burkhard Blank,
Chief Medical Officer and Head of R&D -
Lauren Sabella,
Chief Commercial Officer -
David Lawrence,
Chief Business Operations, Principal Accounting Officer -
Dr. Burkhard Blank M.D.,
Consultant -
Lauren M. Sabella,
Chief Operating Officer -
Peder Jensen,
Independent Director -
John Kelley,
Non-Executive Independent Chairman of the Board -
Lorin Randall,
Independent Director -
Sandra Panem,
Independent Director -
Barry Greene,
Independent Director -
Catherine Strader,
Independent Director -
Neil S. Belloff Esq.,
Gen. Counsel -
Michael A. Gesser M.B.A.,
Chief Financial Officer -
Dr. Wise Young M.D., Ph.D.,
Special Scientific Advisor -
Kerry M. Clem,
Chief Commercial Officer -
Robert Morales,
Interim Principal Accounting Officer, Principal Financial Officer, VP of Fin. & Controller -
Peter S. Carbone,
Exec. VP of Quality -
Dr. Andrew R. Blight,
Chief Scientific Officer Emeritus -
Denise J. Duca,
Exec. VP of HR -
Tierney Saccavino,
Exec. VP of Corp. Communications -
Andrew Mayer J.D.,
Sr. VP, Deputy Gen. Counsel & Corp. Sec. -
Felicia Vonella,
VP of Investor Relations -
Ian F Smith,
Director -
Richard P. Batycky,
Chief Tech. Off. & Site Head -
Steven M Rauscher,
Director -
Capital Management Lp Scopi...,
-
Kerry M Clem,
Chief Commercial Officer -
Wise Young,
Director -
Thomas Wessel,
Chief Medical Officer -
Andrew A. Hindman,
Chief Business Dev. Officer -
Barclay A Phillips,
Director -
Capital Investments Ltd.Rid...,
-
Mark R E Pinney,
Director -
Michael Steinmetz,
Director -
Standish Fleming,
Director -
John H Friedman,
Director -
Mary Fisher,
Chief Operating Officer -
Michael W Rogers,
Chief Financial Officer -
Enrique J. Carrazana,
Chief Medical Officer -
Jane Wasman,
President, Intl and GC -
Robert Morales,
Interim PAO & PFO -
John Varian,
Director -
Michael A Gesser,
Chief Financial Officer -
Thomas M. Burns,
Director -
Neil S. Belloff,
General Counsel and Corp Secy